Betting heavily on innovation—couldn't that be Northeast Pharmaceutical's long-term strategy?

Ask AI · How will breakthrough in innovative drug pipelines reshape a company’s competitive landscape?

Produced by | China Visit Network

Reviewed by | Li Xiaoyan

On April 3, Northeast Pharmaceutical released its 2025 annual report. Against the backdrop of a deep reshuffle in the pharmaceutical industry, normalized centralized procurement, and continued intensification of medical insurance cost controls, the company faced pressure on short-term performance. For the full year, it achieved operating revenue of 7.08B yuan, down 5.70% year over year; attributable net profit was 260 million yuan, down 36.54% year over year. Although this set of results is undeniably bumpy, the data shows that Northeast Pharmaceutical is推进转型 with firm strategic resolve, driving progress on multiple fronts—cost reduction and efficiency improvement, research and development breakthroughs, innovation, and international expansion—to build strong momentum for high-quality development, demonstrating the resilience and potential of a long-established pharmaceutical company navigating through cycles.

Despite intensifying industry competition and price-war pressure on traditional businesses, Northeast Pharmaceutical’s fundamentals remain stable, with core operating quality continuously improving. In 2025, net cash flow from operating activities reached 1.11B yuan, up 45.81% year over year, indicating a significant strengthening of cash collection ability and providing solid funding support for R&D spending, strategic planning, and sound operations. Meanwhile, the company is actively advancing “cost-cutting” measures: selling expenses decreased 8.49% year over year to 1.26B yuan, and administrative expenses fell 5.28% to 702 million yuan. The results of expense control have been significant, and internal operational efficiency continues to improve steadily.

In the face of fierce price competition in bulk raw materials drug markets such as vitamins and antibiotics, Northeast Pharmaceutical has actively adjusted its market strategy. Its export business grew 20.55% against the trend, reaching revenue of 1.09B yuan, becoming a standout in performance. Leveraging product quality advantages in bulk raw materials and international certifications, the company is accelerating expansion into emerging markets such as South America, Africa, and Southeast Asia, effectively offsetting the impact of domestic market contraction. In addition, the company continues to prioritize returning value to shareholders, proposing to distribute 0.55 yuan in cash for every 10 shares (inclusive of tax), with total dividends of approximately 78.49 million yuan, conveying confidence in long-term development.

During the pain of transformation, Northeast Pharmaceutical views innovation as the key to breaking through. R&D investment rose sharply against the trend, becoming the brightest positive signal. In 2025, the company’s R&D investment reached 206 million yuan, up 38.50% year over year. The ratio of R&D investment to revenue increased to 2.91%, reaching the highest level in recent years. Even more noteworthy is the optimization and upgrade of its R&D talent pipeline: the number of R&D personnel increased to 855. Among them, the increases for master’s, doctoral, and young researchers under 30 were 66.97%, 60.00%, and 79.66%, respectively. A younger, more highly educated R&D team lays a solid foundation for technical breakthroughs.

In its innovative drug portfolio, the company has achieved a rapid entry into the TCR-T and CAR-T cell therapy frontier by holding Beijing Dingcheng Peptide Source. Significant breakthrough progress has been made in core pipelines. The DCTY1102 injection was approved for clinical trials, and is expected to become the world’s second and China’s first targeted KRAS G12D TCR-T cell therapy drug, filling the domestic technical gap; the DCTY0801 injection has already obtained orphan drug qualification from the U.S. FDA, and in September 2025 it received a domestic clinical trial approval letter. International clinical progress is proceeding smoothly. Although Dingcheng Peptide Source incurred a loss of 114 million yuan in the period, innovative drug R&D is inherently a long-cycle, high-investment process. Interim losses are consistent with industry norms. Meanwhile, clinical breakthroughs for core products have opened up a medium- to long-term growth space for the company.

Faced with challenges such as a single product structure and pressure on gross margins from traditional generic drugs, Northeast Pharmaceutical clearly stated in its annual report a “one body with two wings” development strategy: to make optimized and strengthened chemical generics as the main body, and to use biologics and health products as well as traditional Chinese medicine as the two wings, forming a development pattern where the core business is solid and diversified synergies drive growth. This strategy not only takes root in the present—consolidating the company’s traditional advantages in bulk raw materials and formulations—but also looks ahead by laying out high-value-added innovative drugs and the health-products track, balancing short-term profitability with long-term development.

On the traditional business side, the company continues to advance consistency evaluations of generics and product upgrades. Products such as the raw materials for efavirenz and the sustained-release tablets of levetiracetam have been approved for listing, and the “raw materials + formulations” integration advantage continues to strengthen. On the emerging business side, health products are accelerating into real-world implementation. Relying on the advantages of pharmaceutical-grade quality, health-and-wellness foods that are edible and medicinal, functional skincare products, and others are gradually opening up the market, becoming new drivers of revenue growth. At the same time, the company is actively revitalizing older product categories and enriching its product matrix to expand its boundaries for people’s livelihood health services in an all-around way.

2025 is a key year for Northeast Pharmaceutical to build up and power its transformation and development. Short-term performance fluctuations are the normal pains of the industry adjustment period, and also an inevitable process in which the company actively seeks change and lays out the future. At present, the company’s traditional business base is solid with ample cash flow; its innovative drug pipeline has entered a clinical value-realization period; the “one body with two wings” strategic path is clear; and both cost reduction and efficiency improvement and R&D innovation are being pursued in a two-way push.

With clinical progress of cell therapy products advancing, the health-products business gradually ramping up in scale, and international markets continuing to expand, Northeast Pharmaceutical is accelerating its transformation from a traditional generic pharmaceutical company into a comprehensive healthcare and pharmaceutical enterprise characterized by “innovation-led, diversified synergy.” Short-term pains do not change the underlying tone of long-term growth. This long-established pharmaceutical company is writing a new chapter of upgrade and renewal, driven by firm transformation resolve and solid strategic execution, riding the wave of high-quality development in the pharmaceutical industry.